Salute e Benessere
Novo Nordisk A/S - share repurchase programme
– On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
Under the programme initiated 11 November 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 3,136,206,122.30 in the period from 11 November 2024 to 3 February 2025.
Since the announcement 20 January 2025, the following transactions have been made:
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 25,365,731 B shares of DKK 0.10 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 24 January 2025, Novo Nordisk has since 6 February 2024 repurchased a total 24,221,173 B shares at an average share price of DKK 811.08 per B share equal to a transaction value of DKK 19,645,420,230.
Company announcement No 05/2025
Attachments
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti